Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat Accumulation

Next Previous
Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat Accumulation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tesamorelin (Primary)
  • Indications HIV-associated lipodystrophy syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Theratechnologies

Most Recent Events

  • 09 Oct 2024 According to Thera Technologies media release, impact of Tesamorelin on cardiovascular disease risk prediction scores in Phase 3 Studies treatment arms: Subanalysis, will be presented in a poster session at IDWeek 2024, on Thursday, October 17, 2024, 12:15 PM -1:30 PM PT.
  • 22 Feb 2023 Results (n=400) assessing whether treatment with tesamorelin was associated with changes in Metabolic Syndrome classification from 2 Phase III trials of tesamorelin, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
  • 22 Feb 2023 Results presented in the Thera Technologies media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top